SOUTH PLAINFIELD, N.J., May 2 /PRNewswire/ -- PTC Therapeutics, Inc.
(PTC), a biopharmaceutical company focused on the discovery and development
of orally administered, proprietary small-molecule drugs that target post-
transcriptional control processes, today announced the promotion of Neil
Almstead to Senior Vice President of Chemistry and CMC, Chemistry
Manufacturing and Controls.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )
"Neil was one of the first ten employees at PTC," commented Stuart
Peltz, Ph.D., President and CEO of PTC Therapeutics, Inc. "He was
instrumental in establishing our chemistry capabilities which now include
medicinal chemistry, analytical chemistry, chemistry informatics and
formulation. Neil has directed multiple successful lead optimization
programs and has developed CMC and manufacturing capabilities to support
PTC's clinical programs. I am extremely pleased to announce Neil's
promotion and look forward to working with him through the next stage of
PTC's growth and development."
"I am honored to be a part of a phenomenal team here at PTC," said Dr.
Almstead. "From our early drug discovery efforts through to the clinic, we
have an excellent track record of accomplishments. I look forward to
working with Stuart and my other colleagues on the further clinical
development of PTC124 and PTC299 as well as advancing our numerous other
programs."
Dr. Almstead joined PTC from Procter & Gamble (P&G) where he was
directly involved in the areas of inflammatory diseases and oncology. At
P&G he was project leader for both the Matrix Metalloproteinase and Map
kinase inhibitor projects. Dr. Almstead has coauthored more than 75
publications and patents pertaining to the design and synthesis of lead
candidate compounds for genetic disorders, oncology and inflammatory
diseases. After receiving his Ph.D. in Organic Chemistry from the
University of Illinois at Urbana-Champaign under the direction of Professor
Scott Denmark, Dr. Almstead was a postdoctoral associate at the University
of Basel in Switzerland with Professor Bernd Giese.
About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery and
development of orally administered, proprietary, small-molecule drugs that
target post-transcriptional control processes. Post-transcriptional control
processes regulate the rate and timing of protein production and are of
central importance to proper cellular function. PTC's internally-discovered
pipeline addresses multiple therapeutic areas, including genetic disorders,
oncology, and infectious diseases. In addition, PTC has developed
proprietary technologies and extensive knowledge of post-transcriptional
control processes that it applies in its drug discovery and development
activities, including the Gene Expression Modulation by Small-molecules
(GEMS) technology platform, which has been the basis for collaborations
with leading pharmaceutical and biotechnology companies such as Pfizer, CV
Therapeutics, and Schering-Plough.
SOURCE PTC Therapeutics, Inc.
 back to top
Related links:
http://www.ptcbio.com/
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Jane Baj of PTC Therapeutics, Inc.,
+1-908-222-7000, x167, jbaj@ptcbio.com; or Sheryl Seapy of Pure
Communications, +1-949-608-0841,
sheryl@purecommunicationsinc.com, for PTC Therapeutics, Inc.
|
